GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Braxia Scientific Corp (XCNQ:BRAX) » Definitions » Debt-to-EBITDA

Braxia Scientific (XCNQ:BRAX) Debt-to-EBITDA : -0.20 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Braxia Scientific Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Braxia Scientific's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.14 Mil. Braxia Scientific's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.50 Mil. Braxia Scientific's annualized EBITDA for the quarter that ended in Dec. 2023 was C$-3.23 Mil. Braxia Scientific's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.20.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Braxia Scientific's Debt-to-EBITDA or its related term are showing as below:

XCNQ:BRAX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.07   Med: -0.02   Max: 0
Current: -0.07

XCNQ:BRAX's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs XCNQ:BRAX: -0.07

Braxia Scientific Debt-to-EBITDA Historical Data

The historical data trend for Braxia Scientific's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Braxia Scientific Debt-to-EBITDA Chart

Braxia Scientific Annual Data
Trend Mar21 Mar22 Mar23
Debt-to-EBITDA
- -0.02 -0.02

Braxia Scientific Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.01 -0.07 -0.94 -0.20

Competitive Comparison of Braxia Scientific's Debt-to-EBITDA

For the Biotechnology subindustry, Braxia Scientific's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Braxia Scientific's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Braxia Scientific's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Braxia Scientific's Debt-to-EBITDA falls into.



Braxia Scientific Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Braxia Scientific's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.076 + 0.131) / -12.704
=-0.02

Braxia Scientific's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.136 + 0.501) / -3.232
=-0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Braxia Scientific  (XCNQ:BRAX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Braxia Scientific Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Braxia Scientific's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Braxia Scientific (XCNQ:BRAX) Business Description

Traded in Other Exchanges
Address
700 Bay Street, Suite 1903, Toronto, ON, CAN, M5G 1Z6
Braxia Scientific Corp is a research-driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as depressive disorder among others. It is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. The company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.

Braxia Scientific (XCNQ:BRAX) Headlines

No Headlines